PLSE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pulse Biosciences Inc (PLSE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, expanding patent portfolio, and recent IDE approvals for its nsPFA platform indicate significant long-term potential. Despite insider selling and negative EPS, the company's technological advancements and bullish analyst ratings make it a promising investment.
The technical indicators suggest a bullish trend. The MACD is positive and contracting, the RSI is neutral, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 25.767), indicating potential for further upward movement.
Q4 2025 revenue increased by 207% QoQ, showing early commercial traction.
Expansion of patient treatment in Europe and IDE approvals for cardiac clamp programs.
Addition of 67 issued and 77 pending patents in 2025, strengthening its market position.
Bullish analyst ratings and increased price targets, with Mizuho raising the target to $30.
Insider selling has increased significantly (3201.34% over the last month).
Negative net income and EPS in Q4 2025, indicating ongoing financial challenges.
In Q4 2025, revenue increased to $264,000 (up 207% QoQ), but net income dropped to -$17.43 million (-10.07% YoY) and EPS fell to -$0.26 (-16.13% YoY). Gross margin improved slightly but remains negative at -54%.
Analysts are bullish on PLSE. Mizuho recently raised the price target to $30 from $25, citing strong adoption potential for the company's nsPFA technology and positive feedback from physicians. The stock is rated Outperform.
